Last reviewed · How we verify
Escitalopram Pill
Escitalopram Pill, developed by Peking University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, supported by a strong patent protection until 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Escitalopram Pill |
|---|---|
| Also known as | Lexapro, no other names |
| Sponsor | Peking University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease (PHASE2)
- Acupuncture and Escitalopram for Treating Major Depression Clinical Study (NA)
- Escitalopram and Language Intervention for Subacute Aphasia (PHASE2)
- Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO) (PHASE4)
- Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression (PHASE4)
- Serotonergic Modulation of Cognition, Emotion and Brain Activation in Healthy Volunteers (PHASE4)
- Stress and Inflammation in Late-Life Depression (PHASE4)
- Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Escitalopram Pill CI brief — competitive landscape report
- Escitalopram Pill updates RSS · CI watch RSS
- Peking University portfolio CI